Enliven Therapeutics (NASDAQ:ELVN) Reaches New 12-Month High – Here’s What Happened

Enliven Therapeutics, Inc. (NASDAQ:ELVN) shares reached a new 52-week high during mid-day trading on Friday . The company traded as high as $47.26 and last traded at $47.1530, with a volume of 72470 shares. The stock had previously closed at $45.34.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on ELVN shares. Wall Street Zen downgraded shares of Enliven Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Wednesday, January 21st. Mizuho raised their price objective on Enliven Therapeutics from $41.00 to $45.00 and gave the company an “outperform” rating in a research report on Wednesday, March 25th. Finally, HC Wainwright upped their target price on Enliven Therapeutics from $48.00 to $56.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Enliven Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.40.

Enliven Therapeutics Stock Up 5.3%

The firm’s 50 day moving average price is $32.79 and its two-hundred day moving average price is $25.15. The firm has a market capitalization of $2.85 billion, a PE ratio of -25.66 and a beta of 0.26.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.06). On average, sell-side analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Enliven Therapeutics news, Director Richard A. Heyman sold 1,230 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $26.18, for a total value of $32,201.40. Following the transaction, the director directly owned 22,647 shares of the company’s stock, valued at $592,898.46. This represents a 5.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Benjamin Hohl sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $29.58, for a total transaction of $295,800.00. Following the sale, the chief financial officer directly owned 51,000 shares of the company’s stock, valued at $1,508,580. The trade was a 16.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 37,460 shares of company stock worth $1,041,104 in the last three months. 25.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Enliven Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. increased its holdings in Enliven Therapeutics by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after buying an additional 594 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in shares of Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after acquiring an additional 930 shares during the last quarter. Los Angeles Capital Management LLC acquired a new stake in shares of Enliven Therapeutics during the 4th quarter valued at approximately $83,000. Quantbot Technologies LP lifted its stake in Enliven Therapeutics by 47.1% during the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after purchasing an additional 1,434 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Enliven Therapeutics in the fourth quarter worth $95,000. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.